
Denosumab: A cost-effective alternative for older men with osteoporosis from a Swedish payer perspective
Keywords: ADAMO; A multicenter, randomized, double-blind, placebo-controlled study to compare the efficacy and safety of DenosumAb 60Â mg every six months versus placebo in Males with Osteoporosis; BMD; Bone mineral density; DAPS; Denosumab Adherence Preference Sat